Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives.
View/ Open
Date
2017-01-01Author
Szopa, W
Burley, TA
Kramer-Marek, G
Kaspera, W
Type
Journal Article
Metadata
Show full item recordAbstract
Glioblastoma (GBM) is a primary neuroepithelial tumor of the central nervous system, characterized by an extremely aggressive clinical phenotype. Patients with GBM have a poor prognosis and only 3-5% of them survive for more than 5 years. The current GBM treatment standards include maximal resection followed by radiotherapy with concomitant and adjuvant therapies. Despite these aggressive therapeutic regimens, the majority of patients suffer recurrence due to molecular heterogeneity of GBM. Consequently, a number of potential diagnostic, prognostic, and predictive biomarkers have been investigated. Some of them, such as IDH mutations, 1p19q deletion, MGMT promoter methylation, and EGFRvIII amplification are frequently tested in routine clinical practice. With the development of sequencing technology, detailed characterization of GBM molecular signatures has facilitated a more personalized therapeutic approach and contributed to the development of a new generation of anti-GBM therapies such as molecular inhibitors targeting growth factor receptors, vaccines, antibody-based drug conjugates, and more recently inhibitors blocking the immune checkpoints. In this article, we review the exciting progress towards elucidating the potential of current and novel GBM biomarkers and discuss their implications for clinical practice.
Collections
Subject
Immune System
Humans
Glioblastoma
Brain Neoplasms
Neoplasm Recurrence, Local
DNA Repair Enzymes
DNA Modification Methylases
Isocitrate Dehydrogenase
Tumor Suppressor Proteins
Prognosis
Medical Oncology
Signal Transduction
DNA Methylation
Gene Deletion
Phenotype
Mutation
Adult
Middle Aged
Female
Male
Promoter Regions, Genetic
ErbB Receptors
Biomarkers, Tumor
Research team
Preclinical Molecular Imaging
Language
eng
Date accepted
2016-12-13
License start date
2017-01
Citation
BioMed research international, 2017, 2017 pp. 8013575 - ?
Publisher
HINDAWI LTD